The National Medical Commission (NMC) has issued a public notice directing all medical colleges/ hospitals under the NMC to get themselves enrolled with the with Indian Pharmacopoeia Commission (IPC) as Adverse Drug Monitoring Centres (AMCs). This direction was issued on 25th January, 2023 and must be complied with at the earliest.
The notice informs all recognized medical colleges and standalone PG institutions that Indian Pharmacopoeia Commission (IPC) is functioning as the National Co-ordination Centre, Pharmacovigilance Programme of India (PvPI). It collects, analyses and monitors the adverse drug reactions (ADRs) from Indian population. In doing so, it promotes patient safety and safeguards the health of patients by ensuring that the benefits of use of medicines outweigh the risk associated with its use.
The collected ADRs data also serves as a major source of evidence for recommendations of regulatory interventions regarding safety of medicines to the Central Drugs Standard Control Organization (CDSCO).
So far, IPC has enrolled 652 Adverse Drug Monitoring Centres (AMCs). Moreover, in the 22nd Meeting of the Governing Body of IPC held on 14.10.2022, it was decided that all Medical colleges/ hospitals under the National Medical Commission should also be enrolled as AMCs with IPC.
Therefore, all Medical colleges/hospitals under the National Medical Commission are directed to get themselves enrolled with Indian Pharmacopoeia Commission (IPC) as AMCs at the earliest.
